News » National

Updated: April 2, 2013 01:12 IST

We will not yield to pressure to grant patents, says Sharma

Sujay Mehdudia
Comment   ·   print   ·   T  T  
Anand Sharma
Anand Sharma

Union Commerce and Industry Minister Anand Sharma has termed “historic” the Supreme Court’s rejection of Novartis’ claim for patent for its anti-cancer drug Glivec.

He said the Indian Patent Act was in conformity with its international obligations under the Trade Related Aspects of Intellectual Property Rights Agreement. “It is a historic judgment. It reaffirms the position of Indian law and, in particular, provisions of Section 3D, which mandates… a substantive innovation… for grant of a fresh patent,” he said in a statement here.

Along with his Ministry, Mr. Sharma has been a strong votary of a compulsory licensing regime and has favoured no-compromise approach to the issue of life-saving drugs. “We have a commitment to the people of India, especially the poor, and will not succumb to any kind of pressure to grant patents beyond their normal lives….”

Novartis does not have a patent for Glivec in the Indian market as the drug was introduced here before India adopted its new patent regime.

However, since the new version of the drug is just a small improvement on the older one, India has rejected the company’s patent appli cation.

This article is closed for comments.
Please Email the Editor

But 80 per cent voting was recorded in rural areas in the district »


Tamil Nadu

Andhra Pradesh





Recent Article in National

Policemen detain a Tibetan youth activist during a protest outside the Taj Palace hotel where Chinese President Xi Jinping is staying, in New Delhi on Friday.

Tibetans stage protest outside Xi's hotel in New Delhi

Protesters carrying placards that read "Freedom is my birth right", "Freedom of Tibet, Security of India", raised anti-China slogans outside Hotel Taj Palace. »